- Home
- OLMA vs PRCT Comparison
OLMA vs PRCT Comparison
Compare OLMA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLMA | PRCT |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OLMA | PRCT |
|---|---|---|
| Price | $10.90 | $20.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $44.89 | $35.44 |
| AVG Volume (30 Days) | 993.2K | ★ 1.7M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.00 | 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $5.36 | $16.67 |
| 52 Week High | $36.26 | $42.43 |
Technical Indicators
Market Signals| Indicator | OLMA | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 51.92 |
| Support Level | $10.71 | $19.64 |
| Resistance Level | $12.37 | $23.57 |
| Average True Range (ATR) | 0.59 | 1.36 |
| MACD | -0.04 | 0.26 |
| Stochastic Oscillator | 44.62 | 65.66 |
Price Performance
Historical ComparisonAbout OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.